v3.26.1
Summary of Significant Accounting Policies (Details Narrative)
3 Months Ended 6 Months Ended 12 Months Ended
May 22, 2023
$ / shares
Jun. 30, 2026
USD ($)
$ / shares
shares
Jun. 30, 2025
USD ($)
shares
Jun. 30, 2026
USD ($)
Segment
$ / shares
shares
Jun. 30, 2025
USD ($)
shares
Dec. 31, 2025
USD ($)
$ / shares
shares
Mar. 31, 2026
USD ($)
Nov. 03, 2025
$ / shares
shares
Nov. 02, 2025
shares
Mar. 31, 2025
USD ($)
Sep. 05, 2023
$ / shares
shares
Sep. 04, 2023
shares
Product Information [Line Items]                        
Reverse stock split 1-for-5                      
Common stock par value | $ / shares $ 0.001 $ 0.001   $ 0.001   $ 0.001         $ 0.001  
Common stock authorized | shares   5,000,000,000   5,000,000,000   5,000,000,000         250,000,000 3,000,000
Goodwill, Impairment Loss   $ 218,606              
Provision for doubtful accounts   36 293 85 (6) $ (109)            
Provision for doubtful accounts   (36) (293) (85) 6 109            
Inventory write down   990 2,354 4,671              
Unrealized gain   42,124,539 42,918,751              
Research and development expense   520 910              
Income tax expense   7,809,615 (997) 7,809,615 (63,257)              
Accumulated undistributed loss   21,800,000   21,800,000   21,700,000            
Unrecognized tax benefits            
Unrecognized tax benefits affect the effective tax rate                
Penalties and interest expense                    
Income tax penalties and interest                
Number of Reportable Segments | Segment       3                
Contract liabilities   $ 189,466   $ 189,466   58,786            
Accounts Payable [Member] | Customer Concentration Risk [Member] | One Customer [Member]                        
Product Information [Line Items]                        
Concentration risk percentage   21.00%   13.00%                
Accounts Payable [Member] | Customer Concentration Risk [Member] | Two Customer [Member]                        
Product Information [Line Items]                        
Concentration risk percentage   17.00%   10.00%                
Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]                        
Product Information [Line Items]                        
Advances to suppliers   $ 283,103 14,970 $ 283,103 14,970              
Accounts payable                
Restricted Stock [Member]                        
Product Information [Line Items]                        
Anti-dilutive shares exercisable | shares   0 1,500 0 1,500              
Warrant [Member]                        
Product Information [Line Items]                        
Anti-dilutive shares exercisable | shares   245,192 245,192 245,192 245,192              
Continuing Operations [Member]                        
Product Information [Line Items]                        
Research and development expense     $ 520   $ 910              
Shipping and handling (credits) costs   1,756 277              
Advertising expense   $ 81,872 $ 88,340 $ 183,858 $ 103,720              
Continuing Operations [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Major Vendor One And Two [Member]                        
Product Information [Line Items]                        
Concentration risk percentage   58.00% 29.00% 46.00% 24.00%              
Continuing Operations [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Major Vendor One [Member]                        
Product Information [Line Items]                        
Concentration risk percentage   16.00% 12.00% 19.00% 14.00%              
Continuing Operations [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Major Vendor Two [Member]                        
Product Information [Line Items]                        
Concentration risk percentage   42.00% 17.00% 27.00% 10.00%              
Preamble Capital LLC [Member]                        
Product Information [Line Items]                        
Equity method investments   $ 31,310,000   $ 31,310,000   22,820,000            
Unrealized gain   42,120,000 42,920,000              
Investments fair value   $ 73,820,000   $ 73,820,000   $ 23,100,000            
Computer Software [Member]                        
Product Information [Line Items]                        
Estimated useful life   5 years   5 years                
Board of Directors Chairman [Member]                        
Product Information [Line Items]                        
Common stock par value | $ / shares               $ 0.001        
Common stock authorized | shares               5,000,000,000 250,000,000